MedNous | Business of medical innovation

Evernow Publishing Ltd Privacy Policy. Read more.

Free featured article

Roche in-licenses new precision therapy

Country

Switzerland

Roche has struck a licensing and collaboration agreement with US-based Blueprint Medicines Corp for a drug entering registration for a group of cancers exhibiting mutations activated by the RET gene. The drug, pralsetinib, is being positioned to treat RET-altered non-small cell lung cancer, various types of thyroid cancer and other solid tumours.

Tecentriq misses endpoint in ovarian cancer

Country

Switzerland

The checkpoint antibody, Tecentriq (atezolizumab), in combination with three other drugs, did not meet its primary endpoint of progression-free survival in a Phase 3 trial of women with advanced ovarian cancer, the developer Roche announced on 13 July. Tecentriq was being investigated with Avastin (bevacizumab), paclitaxel and carboplatin.

New Nordic Fund

Country

Sweden

A new venture capital fund backed by a syndicate of Swedish and Danish institutions, has been launched in the Nordic region to support promising life science companies. The fund, Eir Ventures I AB, is registered in Sweden as an alternative investment fund and will operate from offices in Stockholm and Copenhagen. On 10 July, it announced a first close of €76 million.